• Go to navigation
  • Go to content
hcp.Symbicort.com

Astrazeneca Worldwide

  • AstraZeneca Websites
az.com

Main navigation

  • Home
  • Prescribing Information
  • Mode of Action
  • Contact Us

Welcome to Symbicort.com

This website is an international information resource for healthcare professionals with an interest in asthma and chronic obstructive pulmonary disease (COPD). This website is not intended to replace the advice of a qualified healthcare professional.

  • If you are a healthcare professional in the US, you should visit MySymbicort
  • If you are a healthcare professional in the UK, you should visit the AstraZeneca UK site
  • If you are a patient, you should visit the Patient Site for asthma or COPD
  • If you are a journalist, you should visit the AstraZeneca Press Office
  • If your country is not listed, you should visit www.AstraZeneca.com

Symbicort® (budesonide/formoterol) is a combination formulation containing Pulmicort® (budesonide), an anti-inflammatory corticosteroid, and Oxis® (formoterol), a rapid-acting and long-lasting bronchodilator.

Symbicort is delivered as an inhalation powder via a single inhaler, the Symbicort Turbuhaler®, in one of two doses: 80/4.5 mcg/inhalation or 160/4.5 mcg/inhalation.

Asthma

Symbicort is indicated in the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting beta2-agonist) is appropriate:

  • patients not adequately controlled with inhaled corticosteroids and ‘as needed’ inhaled short-acting beta2-agonists
    or
  • patients already adequately controlled on both inhaled corticosteroids and long-acting beta2-agonists

COPD

Symptomatic treatment of patients with severe COPD (FEV1 <50% predicted normal) and a history of repeated exacerbations, who have significant symptoms despite regular therapy with long-acting bronchodilators

Please consult local Prescribing Information for Symbicort before use.

Page tools

  • Print
  • Bookmark this page

Information

This website has been produced in accordance with both the ABPI Code of Practice for the Pharmaceutical Industry 2008 and the EFPIA Code on the Promotion of Prescription-only Medicines to, and interactions with, Healthcare Professionals.

Legal notices

  • Legal notice
  • Privacy policy
  • © AstraZeneca 2010